Patents Examined by Suzanne Ziska
  • Patent number: 10111984
    Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 30, 2018
    Assignee: Allergan, Inc.
    Inventors: Karina Heredia Guillen, Ahmet Tezel
  • Patent number: 9907885
    Abstract: The present invention relates to devices and related methods for treating fistulas such as anal or recto-vaginal fistulas, in particular by the use of a seton to secure a tissue growth promoter such as a growth factor and/or fibrin. The various devices are particularly suitable for positioning tissue growth promoters securely within a fistula. Thus, one device comprises a seton and a tissue growth promoter. Further related aspects of the invention included devices comprising an enclosure provided in between portions of a seton, devices comprising a seton and a plurality of holes for enabling the device to be sutured to tissue, devices comprising a probe and a seton that are releasably connectable end-to-end, devices comprising an attachment device to secure the ends of a seton, and devices comprising a fistula plug adapted to be secured to a section.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: March 6, 2018
    Inventor: Michael Robert Burch Keighley
  • Patent number: 9907780
    Abstract: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: March 6, 2018
    Assignee: Pernix Sleep, Inc.
    Inventors: Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Baron Casseday, Meredith Perry, Bryan Knox
  • Patent number: 9895391
    Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 20, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Joseph Desimone, Yogen Saunthararajah
  • Patent number: 9889073
    Abstract: The instant invention relates to a color changing composition in the form of an emulsion comprising, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least partially neutralized, crosslinked acrylic homopolymers or copolymers preferably in a non-particulate form.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 13, 2018
    Assignee: L'OREAL
    Inventors: Audrey Ricard, Micheline El Achkar
  • Patent number: 9884022
    Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: February 6, 2018
    Assignee: LUPIN LIMITED
    Inventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
  • Patent number: 9884136
    Abstract: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: February 6, 2018
    Assignee: PluroGen Therapeutics, Inc.
    Inventors: George Rodeheaver, Adam Katz
  • Patent number: 9877987
    Abstract: An object of the present invention is to provide spherical activated carbon exhibiting excellent adsorption ability for uremic substances in the body, and particularly for -aminoisobutyric acid. Accordingly, provided is an orally administered adsorbent comprising spherical activated carbon containing not less than 0.5 wt % of nitrogen atoms, having a specific surface area determined by the Brunauer-Emmett-Teller (BET) method of 700 m2/g to 3000 m2, and having an average particle size from 0.01 to 1 mm.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: January 30, 2018
    Inventors: Takashi Wakahoi, Takahiro Akita, Naohiro Sonobe, Mieko Kuwahara
  • Patent number: 9855261
    Abstract: The purpose of the present invention is to provide a polymeric compound in which a camptothecin compound and an anti-cancer effect enhancer, particularly a PARP inhibitor, are bound to a single molecule, whereby it becomes possible to reduce the toxicity to normal cells and deliver and release the two components to an affected area with high efficiency to thereby improve the pharmacological efficacy of the two components. Provided is a polymeric compound represented by general formula (1).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: January 2, 2018
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Keiichiro Yamamoto, Manami Okazaki
  • Patent number: 9844563
    Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: December 19, 2017
    Inventors: Richard A. Zager, Ali C M Johnson
  • Patent number: 9827117
    Abstract: A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 28, 2017
    Assignee: Micell Technologies, Inc.
    Inventors: Doug Taylor, Jim McClain, Clint Smoke, Mike Cole, James DeYoung
  • Patent number: 9827347
    Abstract: A pressure sensitive adhesive composition includes 4-15 w/w % styrene-isoprene-styrene copolymer, 20-35 w/w % styrene-isoprene diblock copolymer, 4-15 w/w % tackifier, 6-18 w/w % paraffin oil, and 30-45 w/w % hydrocolloid. The size of the hydrocolloid is below 40 ?m.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: November 28, 2017
    Assignee: Coloplast A/S
    Inventors: Anders Christian Nielsen, Tune Bjarke Bonné
  • Patent number: 9828452
    Abstract: The present invention describes a process for the synthesis of spherical particles of polyvinyl alcohol—PVA and/or polyvinyl acetate—PVAc with shell nucleus structure from total or partial hydrolysis in a caustic aqueous medium with obtaining particulates of PVA/PVAc with controlled spherical morphology, to be used in vascular embolization.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: November 28, 2017
    Inventors: José Carlos Costa da Silva Pinto, Mariana Araújo Niemeyer Limeira, Fabricio Machado Silva, Priamo Albuquerque Melo, Márcio Nele De Souza, Galdêncio Espinosa Lopez
  • Patent number: 9814553
    Abstract: The present invention provides a semi-crystalline polymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: November 14, 2017
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Lothar Walter Kleiner, Yiwen Tang, Syed Faiyaz Ahmed Hossainy, Florencia Lim, Michael Ngo, Mikael Trollsas, Qing Lin
  • Patent number: 9808560
    Abstract: A method of forming an implantable article includes providing a biodegradable polymer including anti-thrombogenic groups along the length of the biodegradable polymer, biodegradable groups in the backbone of the biodegradable polymer and a plurality of functional groups adapted to react with reactive functional groups on a surface of the implantable article, and reacting at least a portion of the plurality of functional groups with the reactive functional groups on the surface of the implantable article.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: November 7, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Yi Hong, William R Wagner, Sang-Ho Ye
  • Patent number: 9764065
    Abstract: Medical devices are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 19, 2017
    Assignee: Lutonix, Inc.
    Inventor: Lixiao Wang
  • Patent number: 9763968
    Abstract: Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: September 19, 2017
    Inventors: Patrick J. Sinko, Manjeet Deshmukh, Siva N. Priya Anumolu, Anupa R. Menjoge, Marion K. Gordon
  • Patent number: 9763884
    Abstract: The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a second coating comprising a second active ingredient.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: September 19, 2017
    Assignee: EB IP HYBRITABS B.V.
    Inventors: Johannes Martinus Maria Bloemers, Anko Cornelus Eissens, Henderik Willem Frijlink, Leonardus Gerardus Jozef De Leede
  • Patent number: 9764953
    Abstract: The present invention provides for a bio-mimetic polymer capable of catalyzing or mineralizing calcium ion and phosphate ions into an apatite.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: September 19, 2017
    Assignee: The Regents of the University of California
    Inventors: Ronald N. Zuckermann, James J. De Yoreo, Chun-Long Chen, Yung-Ching Chien, Grayson W. Marshall, Sally J. Marshall, Kuniko Saeki
  • Patent number: 9757349
    Abstract: Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: September 12, 2017
    Inventors: Alberto Tejedor Jorge, Alberto Lazaro Fernandez, Sonia Camano Paez, Ana Maria Torres Redondo, Jose Antonio Lazaro Manero, Manuela Castilla Barba, Maria del Carmen De Lucas Collantes